Viral Warts Treatment Market Segmentation:
Treatment Type Segment Analysis
The topical treatment segment is projected to garner the largest revenue share of 45.6% in the market during the discussed timeframe. The dominance of the segment is effectively attributable to their higher prescription rate as a first-line therapy due to their non-invasiveness, cost-effectiveness, and suitability in home-based care. NIH in January 2023 revealed that salicylic acid is the most widely used and well-studied topical agent for the treatment of viral warts, which showcased a clearance rate of about 39% compared to 25% with a placebo.
Type Segment Analysis
The genital warts segment is expected to capture a significant share of 38.5% in the viral warts treatment market by the end of 2035. The growth in the segment is highly subject to the escalating prevalence of HPV, the critical causative agent. In April 2023, KinoPharma and IWAKI SEIYAKU reported that they have initiated a Phase 2 clinical trial to evaluate the efficacy of a novel antiviral ointment targeting human papillomavirus for the treatment of cutaneous warts, which aims to confirm safety and effectiveness in humans following successful preclinical studies.
End user Segment Analysis
Based on end user hospitals segment, it is likely to gain a share of 35.4% in the market during the analyzed timeframe. The capability of the subtype to handle complex cases necessitates advanced procedures such as cryotherapy and electrosurgery. These facilities are equipped with specialized dermatology departments and are the primary point of care for severe, recurrent, or extensive warts, especially genital warts, hence denoting a positive market outlook.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Treatment Type |
|
|
Type |
|
|
End user |
|
|
Location of Wart |
|
|
Mode of Administration |
|
|
Distribution Channel |
|
